Zobrazeno 1 - 10
of 56
pro vyhledávání: '"John C. Byrd"'
Autor:
Krzysztof Mrózek, Jessica Kohlschmidt, James S. Blachly, Deedra Nicolet, Andrew J. Carroll, Kellie J. Archer, Alice S. Mims, Karilyn T. Larkin, Shelley Orwick, Christopher C. Oakes, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Guido Marcucci, Maria R. Baer, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Eisfeld
Publikováno v:
Leukemia. 37:788-798
Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with cytarabine/anthracycline regimens according to the 2022 and 2017 ELN classifications. C
Autor:
Steven Sher, Ethan Whipp, Janek Walker, Pu Zhang, Larry Beaver, Katie Williams, Shelley Orwick, Janani Ravikrishnan, Brandi Walker, Elizabeth Perry, Charles Gregory, Matthew Purcell, Alexander Pan, Pearlly Yan, Lapo Alinari, Amy J. Johnson, Melanie M. Frigault, Joy M. Greer, Ahmed Hamdy, Raquel Izumi, Xiaokui Mo, Deepa Sampath, Jennifer Woyach, James Blachly, John C. Byrd, Rosa Lapalombella
Publikováno v:
Leukemia. 37:326-338
Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective, treatment options are limited. Positive transcription elongation factor
Autor:
Pooja S. Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J. Pollauf, Amy Zheng, Marilly Palettas, Leylah Azali, Seema A. Bhat, John C. Byrd, Michael R. Grever, Kerry A. Rogers, Jennifer A. Woyach, Adam S. Kittai
Publikováno v:
Leukemia.
Autor:
Pooja S. Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J. Pollauf, Amy Zheng, Marilly Palettas, Leylah Azali, Seema A. Bhat, John C. Byrd, Michael R. Grever, Kerry A. Rogers, Jennifer A. Woyach, Adam S. Kittai
Publikováno v:
Leukemia.
Autor:
Audrey Lasry, Bettina Nadorp, Maarten Fornerod, Deedra Nicolet, Huiyun Wu, Christopher J. Walker, Zhengxi Sun, Matthew T. Witkowski, Anastasia N. Tikhonova, Maria Guillamot-Ruano, Geraldine Cayanan, Anna Yeaton, Gabriel Robbins, Esther A. Obeng, Aristotelis Tsirigos, Richard M. Stone, John C. Byrd, Stanley Pounds, William L. Carroll, Tanja A. Gruber, Ann-Kathrin Eisfeld, Iannis Aifantis
Publikováno v:
Nature Cancer.
Autor:
Audrey M. Sigmund, Ying Huang, Amy S. Ruppert, Kami Maddocks, Kerry A. Rogers, Samantha Jaglowski, Seema A. Bhat, Adam S. Kittai, Michael R. Grever, John C. Byrd, Jennifer A. Woyach
Publikováno v:
Leukemia. 36:2129-2131
Autor:
Charles S. Kuzma, Harry P. Erba, Mark R. Litzow, Steven Coutre, Scott E. Smith, Richard Stone, Amy S. Ruppert, Allison M Booth, Nancy L. Bartlett, Jeremy S. Abramson, John C. Byrd, Jennifer A. Woyach, Jennifer R. Brown, Richard F. Little, Richard A. Larson, Sumithra J. Mandrekar, Wei Ding, Sreenivasa Nattam, Carolyn Owen, Danielle M. Brander
Publikováno v:
Leukemia
Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles versus continuous ibrutinib, complicate adverse event (AE) compar
Autor:
Sunnia T. Chen, Leylah Azali, Lindsay Rosen, Qiuhong Zhao, Tracy Wiczer, Marilly Palettas, John Gambril, Onaopepo Kola-Kehinde, Patrick Ruz, Sujay Kalathoor, Kerry Rogers, Adam Kittai, Michael Grever, Farrukh Awan, John C. Byrd, Jennifer Woyach, Seema A. Bhat, Daniel Addison
Publikováno v:
Journal of Hematology & Oncology. 15
Background Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel selective second (next)-genera
Autor:
Ying Huang, James L. Fisher, Erin M. Bertino, Samantha Jaglowski, Kami J. Maddocks, Seema A. Bhat, John C. Byrd, Amy S. Ruppert, David A. Bond, Michael R. Grever, Dwight H. Owen, Jennifer A. Woyach, Kerry A. Rogers
Publikováno v:
Leukemia
7511 Background: Patients (pts) with chronic lymphocytic leukemia (CLL) suffer morbidity and mortality from CLL and increased risk for second primary neoplasia (SPN). BTK inhibitors (BTKi) are highly effective for the treatment (tx) of CLL and are as
Autor:
Marius Bill, Bayard L. Powell, John C. Byrd, Brian Giacopelli, Jessica Kohlschmidt, Jonathan E. Kolitz, Dimitrios Papaioannou, Christopher C. Oakes, Ramiro Garzon, Krzysztof Mrózek, Richard Stone, Andrew J. Carroll, Ann-Kathrin Eisfeld, Deedra Nicolet, Clara D. Bloomfield
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Recently, a novel knowledge bank (KB) approach to predict outcomes of individual patients with acute myeloid leukemia (AML) was developed using unbiased machine learning. To validate its prognostic value, we analyzed 1612 adults with de novo AML trea